TME Pharma N.V. (ALTME.PA)

EUR 0.07

(-2.46%)

Operating Expenses Summary of TME Pharma N.V.

  • TME Pharma N.V.'s latest annual operating expenses in 2023 was 5.49 Million EUR , down -44.01% from previous year.
  • TME Pharma N.V.'s latest quarterly operating expenses in 2024 Q2 was 2.67 Million EUR , down 0.0% from previous quarter.
  • TME Pharma N.V. reported a annual operating expenses of 11.99 Million EUR in annual operating expenses 2022, down -10.82% from previous year.
  • TME Pharma N.V. reported a annual operating expenses of 13.45 Million EUR in annual operating expenses 2021, up 133.89% from previous year.
  • TME Pharma N.V. reported a quarterly operating expenses of 1.53 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • TME Pharma N.V. reported a quarterly operating expenses of 5.49 Million EUR for 2023 FY, down -54.18% from previous quarter.

Annual Operating Expenses Chart of TME Pharma N.V. (2023 - 2014)

Historical Annual Operating Expenses of TME Pharma N.V. (2023 - 2014)

Year Operating Expenses Operating Expenses Growth
2023 5.49 Million EUR -44.01%
2022 11.99 Million EUR -10.82%
2021 13.45 Million EUR 133.89%
2020 5.75 Million EUR 97.29%
2019 2.91 Million EUR -12.65%
2018 3.33 Million EUR -11.49%
2017 3.77 Million EUR -46.39%
2016 7.03 Million EUR -39.79%
2015 11.68 Million EUR 22.91%
2014 9.5 Million EUR 0.0%

Peer Operating Expenses Comparison of TME Pharma N.V.

Name Operating Expenses Operating Expenses Difference
ABIONYX Pharma SA 4.17 Million EUR -31.602%
ABIVAX Société Anonyme 127.37 Million EUR 95.684%
Adocia SA 15.62 Million EUR 64.828%
Aelis Farma SA 18.81 Million EUR 70.79%
Biophytis S.A. 14.33 Million EUR 61.648%
Advicenne S.A. 8.21 Million EUR 33.086%
genOway Société anonyme 16.73 Million EUR 67.159%
IntegraGen SA 5.35 Million EUR -2.699%
Medesis Pharma S.A. 1.56 Million EUR -251.342%
Neovacs S.A. 10.34 Million EUR 46.856%
NFL Biosciences SA 4.37 Million EUR -25.664%
Plant Advanced Technologies SA 2.76 Million EUR -98.817%
Quantum Genomics Société Anonyme 1.71 Million EUR -219.972%
Sensorion SA 27.05 Million EUR 79.681%
Theranexus Société Anonyme 3 Million EUR -82.929%
Valbiotis SA 9.86 Million EUR 44.3%
TheraVet SA 1.64 Million EUR -234.304%
Valerio Therapeutics Société anonyme 20.32 Million EUR 72.948%
argenx SE 1.34 Billion EUR 99.591%
BioSenic S.A. 7.58 Million EUR 27.509%
Celyad Oncology SA 8.49 Million EUR 35.253%
DBV Technologies S.A. 89.4 Million EUR 93.852%
Galapagos NV 327.98 Million EUR 98.324%
Genfit S.A. 54.8 Million EUR 89.97%
GeNeuro SA 14.35 Million EUR 61.713%
Hyloris Pharmaceuticals SA 17.98 Million EUR 69.439%
Innate Pharma S.A. 64.57 Million EUR 91.487%
Inventiva S.A. 120.18 Million EUR 95.426%
MaaT Pharma SA 21.59 Million EUR 74.549%
MedinCell S.A. 32.92 Million EUR 83.303%
Nanobiotix S.A. 58.92 Million EUR 90.672%
Onward Medical N.V. 20.64 Million EUR 73.374%
Oryzon Genomics S.A. 18.49 Million EUR 70.282%
OSE Immunotherapeutics SA 23.58 Million EUR 76.697%
Oxurion NV 12.21 Million EUR 54.994%
Pharming Group N.V. 204.24 Million EUR 97.309%
Poxel S.A. 28.76 Million EUR 80.89%
GenSight Biologics S.A. 32.66 Million EUR 83.169%
Transgene SA 31.23 Million EUR 82.399%
Financière de Tubize SA 114.38 Thousand EUR -4705.532%
UCB SA 2.94 Billion EUR 99.813%
Valneva SE 134.92 Million EUR 95.926%
Vivoryon Therapeutics N.V. 24.69 Million EUR 77.738%